Urinary liver-type fatty acid-binding protein as a Marker for Early Diagnosis of Diabetic Nephropathy in Type 1 Diabetic Children.

Mones M Abushady; Gihan A Fathy; Inas R El-alameey; Abbas Ma; Essam M Galal; Soha A Nasr

doi:10.22159/ajpcr.2018.v11i5.23518

Authors

Mones M Abushady Department of Child Health, Medical Division, National Research Centre, Cairo, Egypt http://orcid.org/0000-0002-0168-7663
Gihan A Fathy Department of Child Health, Medical Division, National Research Centre, Cairo, Egypt
Inas R El-alameey Department of Child Health, Medical Division, National Research Centre, Cairo, Egypt
Abbas Ma Department of Child Health, Medical Division, National Research Centre, Cairo, Egypt
Essam M Galal Department of Child Health, Medical Division, National Research Centre, Cairo, Egypt
Soha A Nasr Department of Clinical Pathology, Medical Division, National Research Centre, Cairo, Egypt.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i5.23518

Keywords:

Urinary L-FABP, type 1 diabetes, diabetic nephropathy, children

Abstract

Â Objectives: Renal failure and premature mortality are fatal prognosis of diabetic nephropathy. To improve patient outcome, early diagnosis of diabetic nephropathy is necessary. The study was designed to evaluate urinary liver-type fatty acid binding protein (L-FABP), as an early biomarker of tubulointerstitial injury, and its association with the clinical characteristics of type 1 diabetic children.

Methods: Fifty randomly selected patients with type 1 diabetes mellitus (DM) attending the diabetes outpatient clinic of Ain Shams University Children's Hospital were included in the study. 50 age and sex-matched healthy subjects were enrolled as controls. Urinary L-FABP, 24 h urine albumin, hemoglobin A1c (HbA1c), serum creatinine, and lipid profile were measured.

Results: Diabetic subjects had higher mean urinary L-FABP than controls (p<0.05). In microalbuminuric diabetic subjects, the mean urinary L-FABP was detected to be significantly higher than that in normoalbuminuric diabetic subjects, and significantly higher values of the mean urinary L-FABP were detected in the microalbuminuric and the normoalbuminuric subjects than the controls (p<0.05). Multiple linear regression analysis showed that duration of DM and HbA1c was the main predictors of urinary L-FABP in diabetic subjects.

Conclusion: In patients with childhood-onset T1D, urinary L-FABP may be used as an indicator of renal injury in early stages of nephropathy, even in the normoalbuminuric state.

Downloads

Download data is not yet available.

Author Biography

Mones M Abushady, Department of Child Health, Medical Division, National Research Centre, Cairo, Egypt

Child health and nutrition, Child Health Department, National Research Centre, Giza, Egypt.

References

Groop PH, Thomas MC, Moran JL, WadÃ¨n J, Thorn LM, MÃ¤kinen VP, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in Type 1 diabetes. Diabetes 2009;58:1651-8.

Gluhovschi C, Gluhovschi G, Petrica L, Timar R, Velciov S, Ionita I, et al. Urinary biomarkers in the assessment of early diabetic nephropathy. J Diabetes Res 2016;2016:4626125.

Jahidu IM, Sridevi C, Azli SO, Muhammad ZI. Diabetic nephropathy an obvious complication in long term Type 1 diabetes mellitus: A case study. Ascian J Pharm Clin Res 2017;10:4-7.

Atkins RC, Zimmet P. Editorial: Diabetic kidney disease: Act now or pay later. Kidney Int 2010;77:375-7.

Fiseha T, Tamir Z. Urinary markers of tubular injury in early diabetic nephropathy. Int J Nephrol 2016;2016:4647685.

Rossing P, Hougaard P, Parving HH. Progression of microalbuminuria in Type 1 diabetes: Ten-year prospective observational study. Kidney Int 2005;68:1446-50.

Currie G, McKay G, Delles C. Biomarkers in diabetic nephropathy: Present and future. World J Diabetes 2014;5:763-76.

Perkins BA, Ficociello LH, Roshan B, Warram JH, Krolewski AS. In patients with Type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010;77:57-64.

Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS, et al. Regression of microalbuminuria in Type 1 diabetes. N Engl J Med 2003;348:2285-93.

Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric Type 1 diabetic patients: An indicator of more advanced glomerular lesions. Diabetes 2003;52:1036-40.

Bonventre JV. Can we target tubular damage to prevent renal function decline in diabetes? Semin Nephrol 2012;32:452-62.

Nauta FL, Boertien WE, Bakker SJ, van Goor H, van Oeveren W, de Jong PE, et al. Glomerular and tubular damage markers are elevated in patients with diabetes. Diabetes Care 2011;34:975-81.

Nielsen SE, Sugaya T, Hovind P, Baba T, Parving HH, Rossing P, et al. Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in Type 1 diabetic patients. Diabetes Care 2010;33:1320-4.

Lee CH, Lam KS. Biomarkers of progression in diabetic nephropathy: The past, present and future. J Diabetes Investig 2015;6:247-9.

Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, Yamanouchi M, et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004;165:1243-55.

Kamijo A, Kimura K, Sugaya T, Yamanouchi M, Hikawa A, Hirano N, et al. Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med 2004;143:23-30.

Jerine PS, Evan PS. Global current trends in natural products for diabetes management. Int J Pharm Pharm Sci 2016;8:20-8.

Krolewski AS. Progressive renal decline: The new paradigm of diabetic nephropathy in Type 1 diabetes. Diabetes Care 2015;38:954-62.

Krolewski AS, Niewczas MA, Skupien J, Gohda T, Smiles A, Eckfeldt JH, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care 2014;37:226-34.

Skupien J, Warram JH, Smiles AM, Niewczas MA, Gohda T, Pezzolesi MG, et al. The early decline in renal function in patients with Type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney Int 2012;82:589-97.

Ito H, Yamashita H, Nakashima M, Takaki A, Yukawa C, Matsumoto S, et al. Current metabolic status affects urinary liver-type fatty-acid binding protein in normoalbuminuric patients with Type 2 diabetes. J Clin Med Res 2017;9:366-73.

Benzer M, Tekin Neijmann S, GÃ¼ltekin ND, Uluturk Tekin A. Urinary L-FABP as a marker of vesicoureteral reflux in children: Could it also have a protective effect on the kidney? Int Urol Nephrol 2017;49:1-2.

GÃ¼neÅŸ A, Aktar F, Tan Ä°, SÃ¶ker M, Uluca Ãœ, BalÄ±k H, et al. Urinary levels of early kidney injury molecules in children with vitamin B12 deficiency. Arch Argent Pediatr 2016;114:453-7.

Viswanathan V, Sivakumar S, Sekar V, Umapathy D, Kumpatla S. Clinical significance of urinary liver-type fatty acid binding protein at various stages of nephropathy. Indian J Nephrol 2015;25:269-73.

Panduru NM, Forsblom C, Saraheimo M, Thorn L, Bierhaus A, Humpert PM, et al. Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in Type 1 diabetes. Diabetes Care 2013;36:2077-83.

Kamijo-Ikemori A, Sugaya T, Ichikawa D, Hoshino S, Matsui K, Yokoyama T, et al. Urinary liver type fatty acid binding protein in diabetic nephropathy. Clin Chim Acta 2013;424:104-8.

Chou KM, Lee CC, Chen CH, Sun CY. Clinical value of NGAL, L-FABP and albuminuria in predicting GFR decline in Type 2 diabetes mellitus patients. PLoS One 2013;8:e54863.

Suh JS, Kim SH, Cho KS, Jung IA, Cho WK, Jeon YJ, et al. Urinary markers in the early stage of nephropathy in patients with childhood-onset Type 1 diabetes. Pediatr Nephrol 2016;31:623-31.